WO1996027677A3 - Method of purification of recombinant viral vectors containing a therapeutic gene - Google Patents

Method of purification of recombinant viral vectors containing a therapeutic gene Download PDF

Info

Publication number
WO1996027677A3
WO1996027677A3 PCT/US1996/003369 US9603369W WO9627677A3 WO 1996027677 A3 WO1996027677 A3 WO 1996027677A3 US 9603369 W US9603369 W US 9603369W WO 9627677 A3 WO9627677 A3 WO 9627677A3
Authority
WO
WIPO (PCT)
Prior art keywords
resin
purification
viral vectors
vectors containing
recombinant viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/003369
Other languages
French (fr)
Other versions
WO1996027677A2 (en
Inventor
Paul W Shabram
Bernard G Huyghe
Xiaodong Liu
H Michael Shepard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Priority to EP96911282A priority Critical patent/EP0813606B1/en
Priority to DE69636217T priority patent/DE69636217T2/en
Priority to AU54213/96A priority patent/AU5421396A/en
Priority to CA002214837A priority patent/CA2214837C/en
Priority to JP52708196A priority patent/JP3858200B2/en
Publication of WO1996027677A2 publication Critical patent/WO1996027677A2/en
Publication of WO1996027677A3 publication Critical patent/WO1996027677A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
    • C08F265/02—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of acids, salts or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00—Inks
    • C09D11/02—Printing inks
    • C09D11/10—Printing inks based on artificial resins
    • C09D11/106—Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Plant Pathology (AREA)
  • Materials Engineering (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a method for purifying viral vectors containing therapeutic genes for use in gene therapy. The invention comprises a method of purification from a cell lysate of a recombinant viral vector containing a therapeutic gene, which comprises: a) treating said lysate with an enzymatic agent that selectively degrades both unencapsulated DNA and RNA; b) chromatographing the treated lysate from step a) on a first resin; and c) chromatographing the eluant from step b) on a second resin; wherein one resin is an anion exchange resin and the other is an immobilized metal ion chromatography (IMAC) resin.
PCT/US1996/003369 1995-03-07 1996-03-06 Method of purification of recombinant viral vectors containing a therapeutic gene Ceased WO1996027677A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP96911282A EP0813606B1 (en) 1995-03-07 1996-03-06 Method of purification of recombinant viral vectors containing a therapeutic gene
DE69636217T DE69636217T2 (en) 1995-03-07 1996-03-06 PROCESS FOR PURIFICATION OF RECOMBINANT, VIRAL VECTORS CONTAINING A THERAPEUTIC GENE
AU54213/96A AU5421396A (en) 1995-03-07 1996-03-06 Method of purification of recombinant viral vectors containing a therapeutic gene
CA002214837A CA2214837C (en) 1995-03-07 1996-03-06 Method of purification of recombinant viral vectors containing a therapeutic gene
JP52708196A JP3858200B2 (en) 1995-03-07 1996-03-06 Method for purifying recombinant viral vectors containing therapeutic genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/400,793 US5837520A (en) 1995-03-07 1995-03-07 Method of purification of viral vectors
US08/400,793 1995-03-07

Publications (2)

Publication Number Publication Date
WO1996027677A2 WO1996027677A2 (en) 1996-09-12
WO1996027677A3 true WO1996027677A3 (en) 1997-01-16

Family

ID=23585038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003369 Ceased WO1996027677A2 (en) 1995-03-07 1996-03-06 Method of purification of recombinant viral vectors containing a therapeutic gene

Country Status (12)

Country Link
US (1) US5837520A (en)
EP (2) EP0813606B1 (en)
JP (2) JP3858200B2 (en)
AR (1) AR001177A1 (en)
AT (1) ATE329045T1 (en)
AU (1) AU5421396A (en)
DE (1) DE69636217T2 (en)
DK (1) DK0813606T3 (en)
ES (1) ES2264801T3 (en)
PT (1) PT813606E (en)
WO (1) WO1996027677A2 (en)
ZA (1) ZA961849B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738319A4 (en) * 1994-01-12 2000-03-29 Genetic Therapy Inc Purification of retroviral vectors
FR2737730B1 (en) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
EP0944717A1 (en) * 1996-07-01 1999-09-29 Aventis Pharma S.A. Method for producing recombinant adenovirus
US6475388B1 (en) 1996-11-13 2002-11-05 Transgenomic, Inc. Method and system for RNA analysis by matched ion polynucleotide chromatography
US6576133B2 (en) 1996-11-13 2003-06-10 Transgenomic, Inc Method and system for RNA analysis by matched ion polynucleotide chromatography
ES2278399T3 (en) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS.
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6177559B1 (en) 1998-04-24 2001-01-23 Transgenomic, Inc. Process for separation of polynucleotide fragments
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP2001514845A (en) 1997-09-05 2001-09-18 ターゲティッド ジェネティクス コーポレイション Method for generating a high titer helper-free preparation of a recombinant AAV vector
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1021524A1 (en) * 1997-10-09 2000-07-26 Biogen, Inc. Chromatographically concentrated baculovirus and methods
US6258264B1 (en) 1998-04-10 2001-07-10 Transgenomic, Inc. Non-polar media for polynucleotide separations
US6265168B1 (en) 1998-10-06 2001-07-24 Transgenomic, Inc. Apparatus and method for separating and purifying polynucleotides
JP2002512361A (en) 1998-04-22 2002-04-23 ジェンベク、インコーポレイティッド Efficient purification of adenovirus
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
DK1930418T3 (en) 1998-09-04 2015-07-13 Genzyme Corp Methods for Generating Helper-Free High Titer Preparations of Released Recombinant AAV Vectors
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2356373A1 (en) 1998-12-31 2000-07-13 Aventis Pharma S.A. Method for separating viral particles
EP1155120B1 (en) * 1999-02-22 2006-07-05 Transgene S.A. Method for obtaining a purified viral preparation
DE19933719A1 (en) * 1999-07-19 2001-01-25 Medigene Ag Structural protein in adeno-associated virus with altered chromatographic properties, its production and use
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP4684434B2 (en) * 2000-02-16 2011-05-18 Ｊｓｒ株式会社 Virus concentration particle, virus concentration reagent, virus concentration method and virus detection method
DE10010342A1 (en) * 2000-03-06 2001-09-20 Merck Patent Gmbh Method for reducing the endotoxin content of nucleic acid (I) is derived from natural, genetic engineering or biotechnological sources is used to produce high-purity plasmid DNA from natural sources
DK1285080T3 (en) * 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Process for Purification of Alphavirus Replicon Particles
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002049422A2 (en) * 2000-12-20 2002-06-27 K.U. Leuven Research And Development Non-human animal disease models
KR100451308B1 (en) * 2001-12-28 2004-10-06 선바이오(주) A virus removal process in the purification of biologically active molecules
US6833238B2 (en) 2002-01-04 2004-12-21 Applera Corporation Petal-array support for use with microplates
US7316898B2 (en) * 2002-02-20 2008-01-08 Merck & Co., Inc. Method of determining adenovirus particle concentration
EP1492891B1 (en) * 2002-03-29 2008-02-20 Merck & Co., Inc. Methods of virus production
JP2005521417A (en) * 2002-03-29 2005-07-21 メルク　エンド　カムパニー　インコーポレーテッド Large-scale production method of adenovirus and adenovirus seed stock
DE60335672D1 (en) * 2002-05-14 2011-02-17 Merck Sharp & Dohme PROCESS FOR CLEANING ADENOVIRUS
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
US20040018559A1 (en) * 2002-07-26 2004-01-29 Applera Corporation Size-exclusion ion-exchange particles
CA2496918A1 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
JP2007523621A (en) * 2003-06-18 2007-08-23 オニックス ファーマシューティカルズ，インコーポレイティド Methods for purifying viruses
DK1648931T3 (en) 2003-07-21 2011-03-07 Transgene Sa Multifunctional cytokines
EP1692154A4 (en) * 2003-11-24 2009-07-08 Canji Inc DERMAL HEALING REDUCTION
EP1697505A1 (en) * 2003-12-23 2006-09-06 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
EP2821135A1 (en) * 2004-02-05 2015-01-07 EMD Millipore Corporation Porous adsorptive or chromatographic media
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
WO2006011580A1 (en) * 2004-07-27 2006-02-02 Genomidea, Inc. Method of purifying virus envelope
EP1815029A4 (en) * 2004-11-03 2009-06-10 Introgen Therapeutics Inc A novel method for the production and purification of adenoviral vectors
CA2590943C (en) * 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP1907537A4 (en) * 2005-07-14 2010-11-10 Mayo Foundation PREPARATIONS BASED ON PARAMYXOVIRIDAE VIRUS
DE602006019916D1 (en) * 2005-12-12 2011-03-10 Canji Inc ADENOVIRAL EXPRESSION VECTORS WITH AN EXPRESSION CASSETTE IN THE E1 AREA AND AN INACTIVATED E2B POLYMERASE
WO2008060356A2 (en) * 2006-09-29 2008-05-22 Canji, Inc. Methods and compositions for gene therapy
WO2008092854A2 (en) 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
PL2307551T3 (en) 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Purification of retroviral vectors
SI2349520T1 (en) * 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Purification method for carbohydrate from group a streptococcus
CN102203242B (en) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 Method for the production of adenoviral vectors
TWI555531B (en) 2009-08-07 2016-11-01 傳斯堅公司 Composition for treating hbv infection
MX2012007936A (en) 2010-02-15 2012-11-22 Crucell Holland Bv Method for the production of ad26 adenoviral vectors.
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (en) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Heterologous prime boost vaccination regimen against malaria.
DE102010046817A1 (en) 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh A method for separating viruses from a contaminant-containing liquid medium
JP5940554B2 (en) 2010-12-09 2016-06-29 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ MGMT based method for obtaining high yield of recombinant protein expression
CN103476399A (en) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 Drug delivery particles and method for producing same
TWI623618B (en) 2011-07-12 2018-05-11 傳斯堅公司 Hbv polymerase mutants
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
AU2012320480A1 (en) * 2011-10-05 2014-04-24 Molmed Spa Viral vectors purification system
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
JP5770952B2 (en) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー Batch of recombinant adenoviruses with modified ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EA026504B1 (en) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Vaccine against rsv
CN103571800B (en) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 A kind of method of host DNA in removal vaccine
JP6430949B2 (en) 2012-10-23 2018-11-28 エモリー ユニバーシティ Conjugates, compositions, and related methods of GM-CSF and IL-4
JP6469081B2 (en) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stabilized soluble pre-fusion RSVF polypeptide
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2016166088A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CN107847581B (en) 2015-07-07 2022-03-22 扬森疫苗与预防公司 Stabilized soluble prefusion RSV F polypeptide
ES2839880T3 (en) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv RSV vaccine
US9663766B2 (en) * 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
KR102500970B1 (en) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Vaccine against rsv
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN109154000B (en) 2016-05-12 2022-07-05 扬森疫苗与预防公司 Efficient and balanced bidirectional promoters
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V Stabilized pre-fusion rsv f proteins
KR102307065B1 (en) 2016-06-20 2021-09-30 얀센 백신스 앤드 프리벤션 비.브이. A strong, balanced bidirectional promoter
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
JP7016136B2 (en) 2016-09-05 2022-02-04 国立研究開発法人科学技術振興機構 Methods and kits for detecting pathogenic microorganisms
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN110418650A (en) 2016-11-16 2019-11-05 免疫治疗有限公司 For treating the nucleic acid of allergy
CN110268061B (en) 2017-02-09 2024-07-16 扬森疫苗与预防公司 Efficient short promoters for expression of heterologous genes
KR102637960B1 (en) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. Improved LAMP construct
US12358962B2 (en) 2017-05-02 2025-07-15 Immunomic Therapeutics, Inc. Lamp constructs comprising cancer antigens
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
US12173348B2 (en) 2018-03-02 2024-12-24 Japan Science And Technology Agency Method for detecting enzymatic reaction product
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
CA3113648A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
JP7233880B2 (en) * 2018-10-22 2023-03-07 キヤノンメディカルシステムズ株式会社 Viral RNA isolation method and virus quantification method
JP2022513025A (en) 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Stabilized pre-fusion RSVF protein
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
EP3927833A4 (en) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
EP4045528A1 (en) 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
KR20220115569A (en) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 Vaccines based on mutant CALR and JAK2 and uses thereof
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
EP4135757A1 (en) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP7526360B2 (en) * 2020-08-18 2024-07-31 ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． Multimodal metal affinity engineered AAV capsids
US20250352639A1 (en) 2022-04-10 2025-11-20 Immunomic Therapeutics, Inc. Bicistronic LAMP Constructs Comprising Immune Response Enhancing Genes and Methods of Use Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004696A1 (en) * 1983-05-31 1984-12-06 Baxter Travenol Lab Particle adsorption
WO1995002688A1 (en) * 1993-07-16 1995-01-26 Chiron Viagene, Inc. Methods and compositions for the removal of viruses and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004696A1 (en) * 1983-05-31 1984-12-06 Baxter Travenol Lab Particle adsorption
WO1995002688A1 (en) * 1993-07-16 1995-01-26 Chiron Viagene, Inc. Methods and compositions for the removal of viruses and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUYGHE, BERNARD G. ET AL: "Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography", HUM. GENE THER. (1995), 6(11), 1403-16 CODEN: HGTHE3;ISSN: 1043-0342, November 1995 (1995-11-01), XP000601674 *
I. HARUNA ET AL: "Separation of Adenovirus by chromatography on DEAE-cellulose", VIROLOGY, vol. 13, 1961, pages 264 - 267, XP000601693 *
J. TAVERNE ET AL: "The purification and concentration of viruses and virus soluble antigens on calcium phosphate", JOURNAL OF GENERAL MICRBIOLOGY, vol. 19, 1958, pages 451 - 455, XP002012869 *
P. O'NEIL AND E. BALKOVIC: "Virus harvesting and affinity-based liquid chromatography", BIOTECHNOLOGY, vol. 11, 1993, pages 173 - 178, XP000195205 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Also Published As

Publication number Publication date
EP0813606A2 (en) 1997-12-29
JP2000510682A (en) 2000-08-22
ATE329045T1 (en) 2006-06-15
JP3858200B2 (en) 2006-12-13
EP1686180A2 (en) 2006-08-02
EP0813606B1 (en) 2006-06-07
US5837520A (en) 1998-11-17
WO1996027677A2 (en) 1996-09-12
ZA961849B (en) 1997-08-27
JP2006271396A (en) 2006-10-12
JP4182445B2 (en) 2008-11-19
ES2264801T3 (en) 2007-01-16
EP1686180A3 (en) 2006-08-09
DE69636217D1 (en) 2006-07-20
DE69636217T2 (en) 2007-04-26
PT813606E (en) 2006-10-31
DK0813606T3 (en) 2006-10-02
AR001177A1 (en) 1997-09-24
AU5421396A (en) 1996-09-23

Similar Documents

Publication Publication Date Title
WO1996027677A3 (en) Method of purification of recombinant viral vectors containing a therapeutic gene
AU1664695A (en) Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
WO1997021826A3 (en) Complementary adenoviral vector systems and cell lines
EP1541690A3 (en) Transfer of mRNA using polycationic compounds
WO1998039463A3 (en) Lentivirus based vector and vector system
DE69636866D1 (en) Reverse "two-hybrid"-systeme
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
WO1997012986A3 (en) Non-group c adenoviral vectors
IL123649A0 (en) Regulated genes and uses thereof
Takahashi-Nakamura et al. Purification and characterization of an inhibitor of calcium-activated neutral protease from rabbit skeletal muscle
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
IL162477A0 (en) Nucleic acid molecules encoding delta-5,7-sterol, delta-7 reductase from arabidopsis thaliana
WO2001058494A3 (en) Gene therapy for treating ocular-related disorders
HUT75717A (en) Nucleic acid molecules encoding cytoplasmatic alcohol dehydrogenase and glutamil-cystein synthetase, vectors to introduce them and processes employing these vectors
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
WO1997023611A3 (en) Nucleic acid sequences of genes of the high mobility group proteins and uses thereof
CA2214837A1 (en) Method of purification of recombinant viral vectors containing a therapeutic gene
Pero et al. In vitro transcription of a late class of phage SP01 genes
CA2260765A1 (en) Purified proteins, recombinant dna sequences and processes for controlling the ripening of coffee plants
WO2001088124A3 (en) Method and reagent for the inhibition of erg
WO2001027254A3 (en) Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy
EP0707655A1 (en) Dna expression vectors for use in the treatment of vascular diseases by gene therapy
WO1996018737A3 (en) Vectors and viruses for use in gene therapy
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy
Murao et al. Nucleotide sequence of valine t RNA mo 5 UAC from Bacillus subtilis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2214837

Country of ref document: CA

Ref country code: JP

Ref document number: 1996 527081

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2214837

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996911282

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996911282

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996911282

Country of ref document: EP